Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study

MLA

Nobuhiko Uoshima, et al. “Combined Rituximab, Bendamustine, and Dexamethasone Chemotherapy for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma and Mantle Cell Lymphoma: A Multicenter Phase II Study.” International Journal of Hematology, vol. 110, May 2019, pp. 77–85. EBSCOhost, https://doi.org/10.1007/s12185-019-02650-w.

APA

Nobuhiko Uoshima, Tomoko Takimoto-Shimomura, Mitsushige Nakao, Hitoji Uchiyama, Shin-ichi Fuchida, Hisao Nagoshi, Hiroto Kaneko, Kazuho Shimura, Shinsuke Mizutani, Yoshiaki Chinen, Mio Sugitani, Yosuke Matsumoto, Toshiki Iwai, Eri Kawata, Yutaka Kobayashi, Mihoko Yoshida, Tsutomu Kobayashi, Yuji Shimura, Chihiro Shimazaki, … Shigeo Horiike. (2019). Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study. International Journal of Hematology, 110, 77–85. https://doi.org/10.1007/s12185-019-02650-w

Chicago

Nobuhiko Uoshima, Tomoko Takimoto-Shimomura, Mitsushige Nakao, Hitoji Uchiyama, Shin-ichi Fuchida, Hisao Nagoshi, Hiroto Kaneko, et al. 2019. “Combined Rituximab, Bendamustine, and Dexamethasone Chemotherapy for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma and Mantle Cell Lymphoma: A Multicenter Phase II Study.” International Journal of Hematology 110 (May): 77–85. doi:10.1007/s12185-019-02650-w.